Intrahepatic Cholangiocarcinoma

Oncology
2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

BP
Basilea PharmaceuticaSwitzerland - Allschwil
2 programs
1
derazantinibPhase 2Small Molecule1 trial
derazantinibN/ASmall Molecule1 trial
Active Trials
NCT04087876No Longer Available
NCT03230318CompletedEst. Oct 2022
H
HutchmedChina - Hong Kong
1 program
1
HMPL-453Phase 11 trial
Active Trials
NCT05930119Completed24Est. Aug 2023
M&
Merck & Co.RAHWAY, NJ
1 program
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma N/A1 trial
Active Trials
NCT02762721Completed131Est. Apr 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Basilea Pharmaceuticaderazantinib
HutchmedHMPL-453
Merck & Co.Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma

Clinical Trials (4)

Total enrollment: 155 patients across 4 trials

NCT03230318Basilea Pharmaceuticaderazantinib

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Start: Sep 2017Est. completion: Oct 2022
Phase 2Completed
NCT05930119HutchmedHMPL-453

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Start: Mar 2023Est. completion: Aug 202324 patients
Phase 1Completed
NCT04087876Basilea Pharmaceuticaderazantinib

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

N/ANo Longer Available
NCT02762721Merck & Co.Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Start: Jun 2016Est. completion: Apr 2017131 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)